Trump Drug Pricing Deals Face First Test with New Product Launches
Seventeen drugmakers agreed to most-favored-nation pricing commitments with the Trump administration, limiting U.S. launch prices to the lowest prices charged in a reference basket of countries. New drug launches in coming months will reveal whether these voluntary agreements constrain list prices for products entering the market. The agreements lack enforcement mechanisms and apply only to participating manufacturers. For Medicaid managed care organizations, launch pricing affects rebate calculations, formulary positioning, and budget forecasting for high-cost specialty drugs covered under managed care contracts.
Launch prices for new drugs directly impact Medicaid MCO pharmacy spending, rebate revenue, and prior authorization strategies for specialty medications.
Pharmacy · Managed Care · Finance
You might also like